Upon treatment with these agents, human HCC cells (HLE, LCL-PI 11) exhibited increased expression of SOCS1 and SOCS3, resulting in reduced activation of JAK2 and STAT3. This evidence concerns the gene JAK2 and hepatocellular carcinoma.